Clinical trials: Adalimumab
Healthy
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety of human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection and Adalimumab when used…
- Trial name
- NCT02912247
- Testing
- human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, adalimumab
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Rheumatoid Arthritis
Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The purpose of the study is to assess the long-term safety, tolerability, and efficacy of repeated administration of adalimumab in adult Japanese subjects with rheumatoid arthritis.
- Trial name
- NCT00235833
- Testing
- adalimumab
- Where
- 7 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Ankylosing Spondylitis
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira
- Trial name
- NCT04135508
- Testing
- BAT1406, Humira
- Volunteers
- 554 people
- Sponsor
- Bio-Thera Solutions
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with…
- Trial name
- NCT00408629
- Testing
- adalimumab
- Where
- 108 sites in United States, Argentina and 16 more
- Volunteers
- 518 people
- Sponsor
- Abbott
Ulcerative Colitis (UC)
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT02065622
- Testing
- Adalimumab
- Where
- 173 sites in United States, Austria and 18 more
- Volunteers
- 952 people
- Sponsor
- AbbVie
Healthy
Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
- Trial name
- NCT02675023
- Testing
- M923
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Rheumatoid Arthritis
Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance.
- Trial name
- PROWD (NCT00650390)
- Testing
- adalimumab
- Sponsor
- Abbott
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
This study will compare injection site pain levels between current Humira® formulation versus a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either currently on a stable dose (minimum six…
- Trial name
- NCT01502423
- Testing
- Adalimumab
- Where
- 7 sites in Australia, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis.
- Trial name
- PSOLAR (NCT00508547)
- Where
- 320 sites in United States, Argentina and 20 more
- Volunteers
- 20,167 people
- Sponsor
- Janssen Scientific Affairs, LLC
Moderate to Severe Plaque Psoriasis
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.
- Trial name
- NCT01644396
- Testing
- Adalimumab
- Where
- 7 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Early Rheumatoid Arthritis
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy…
- Trial name
- PREMIER (NCT00195663)
- Testing
- Adalimumab, Methotrexate
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 799 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
The primary objective of this study is to evaluate long-term effectiveness of adalimumab in pediatric participants starting a treatment for Crohn's disease in real life conditions, namely to describe the time to loss of clinical…
- Trial name
- LEA (NCT03017014)
- Where
- 24 sites in France
- Volunteers
- 62 people
- Sponsor
- AbbVie
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))
The present survey was conducted to evaluate the effectiveness and safety of treatment with adalimumab during the 52-week period following completion of the treatment period in Study NCT00870467 (M06-859) in participants who…
- Trial name
- NCT01163292
- Where
- 75 sites in Japan
- Volunteers
- 220 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
- Trial name
- VOYAGE 2 (NCT02207244)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 992 people
- Sponsor
- Janssen Research & Development, LLC
Polyarticular Juvenile Idiopathic Arthritis
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage.
- Trial name
- NCT05411211
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AbbVie